FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients
The label change is supported by data from the ARIES-HM3 trial showing less bleeding with no increased risk of thrombosis.
![FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/header_image/public/2024-08/fda%20alert.jpg?itok=VQmLnBeJ)
Pharmacotherapy for advanced heart failure patients with a HeartMate 3 left ventricular assist device (LVAD) is being simplified following US Food and Drug Administration approval of a labeling change that eliminates aspirin from the antithrombotic regimen, device maker Abbott announced today.
The FDA’s decision is based on data from the international ARIES-HM3 trial. As TCTMD previously reported, the study found that an aspirin-free regimen, compared with low-dose aspirin plus vitamin K antagonist therapy, was associated with fewer bleeding events and no increased risk of stroke or other thromboembolic events at 12 months across diverse subgroups of patients.
The ARIES-HM3 investigators estimated that for every 100 patients, avoiding aspirin would prevent 14.5 major bleeding events in the first year after LVAD implantation. As a result of fewer bleeding events, going aspirin-free was projected to decrease days spent in the hospital by 47% and cost of care for bleeding encounters by 41%.
In a press release announcing the approval of the labeling change request, Abbott noted that the elimination of aspirin from the therapeutic regimen applies exclusively to patients who receive a HeartMate 3 device, and that this change has also been approved by regulatory agencies in Canada and the European Union.
L.A. McKeown is a Senior Medical Journalist for TCTMD, the Section Editor of CV Team Forum, and Senior Medical…
Read Full BioSources
Abbott. Abbott advances heart failure management with aspirin free regimen for patients receiving the HeartMate 3 heart pump. Published and accessed on August 21, 2024.
Comments